Physician profile
Susan Azar
NPI 1245222439
$897.27
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2021: $125 · 2023: $122 · 2024: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $387.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $124.99 | 2021 | |
| Apellis Pharmaceuticals, INC. | $121.87 | 2023 | Syfovre |
| Dompe US, INC. | $119.78 | 2024 | Oxervate |
| Carl Zeiss Meditec, INC. | $100.59 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $92.31 | 2019 | |
| Alcon Vision LLC | $91.49 | 2019-2024 | Wavelight Ex500 Excimer Laser, Lensx |
| Optos, INC. | $46.04 | 2019 | |
| Biotissue Holdings INC. | $45.16 | 2019 | |
| Heidelberg Engineering, INC. | $43.80 | 2019 | |
| Glaukos Corporation | $36.03 | 2024 | Ce-Marked Kxla System |
| Abbvie INC. | $30.29 | 2024 | |
| Oyster Point Pharma, INC. | $17.75 | 2024 | Tyrvaya |
| Bausch & Lomb Americas INC. | $15.96 | 2024 | Envista Mx60 Iol |
| Omeros Corporation | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Azar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.